drugset / Trial / NCT01460654
Testosterone and Alendronate in Hypogonadal Men
Phase 2
Terminated
44 enrolled
Massachusetts General Hospital
Endo USA Inc., a Keenova Therapeutics Company · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.
Timeline
- Start
- 2011-10
- Primary completion
- 2014-05
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | 70 mg | — |
| Subject | Testosterone | Small molecule | 40 mg | — |